Form 4: Arrowhead Pharmaceuticals Director Acquires Shares Through Restricted Stock Units

Director Hongbo Lu of Arrowhead Pharmaceuticals acquired 16,733 shares of common stock through restricted stock units on December 18, 2024.

Summary

• Hongbo Lu, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock on December 18, 2024.
• The shares were acquired through restricted stock units at a price of $22.99 per share.
• Following the transaction, Mr. Lu beneficially owns 47,163 shares of Arrowhead Pharmaceuticals stock.
• The restricted stock units will vest in one installment on the first anniversary date.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction by a company director, which is generally viewed positively as it indicates confidence in the company. However, it's not a major event that would drastically alter sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade company stock. It provides transparency into the transactions of company directors.

Comparison to Industry Standards

• This type of transaction is common among publicly traded companies, where directors and officers often receive stock-based compensation.
• The vesting schedule of one year is also a typical practice for restricted stock units.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates

Keywords

Arrowhead Pharmaceuticals, Director, Stock Acquisition, Restricted Stock Units, Beneficial Ownership, ARWR